CVS Add to watchlist $90.98 1.99 (-2.14%) Last updated: May 31, 2026 06:43
52-Week Range
$90.98
$58.50 $90.98 $98.43

Fundamentals Overview

CVS Health Corporation is near the high of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/E 39.7 P/B 1.5 P/S 0.28

Intrinsic value (DCF)

+344.9% upside vs price

Profitability

Net margin 0.7%

Risk (Beta)

0.59 — lower vol

Earnings & growth

EPS $2.29 Rev -5% Profit +0% vs prior qtr

BullzEye Analysis

Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Buy — 80% confidence Risk: Lower Volatility — Beta 0.59. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +344.9% upside vs price · Analyst grade: B+ · Sentiment improving (1 upgrade) · 3M vs S&P 500: +10.3% · 3M vs Healthcare sector: +24.7%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$116.08B
P/E (TTM)
39.69
EPS (TTM)
$2.29
Dividend Yield
2.92%
52-Week Range
$58.50 - $98.43
Volume vs Avg
N/A
Beta
0.59

About

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, includ...
Sector: Healthcare
Headquarters: US
Employees: 300,000
IPO Date: Nov 1996
Beta: 0.59 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 8, Market Perform: 3, Outperform: 8, Overweight: 11.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $404.78; current price is $90.98. That’s a +344.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 39.69
DCF value (model) $404.78 (344.9% upside)
PEG (TTM) N/A
P/B (TTM) 1.5
P/S (TTM) 0.28
P/FCF (TTM) 15.7
Liquidity & enterprise
Current Ratio (TTM) 0.87
Quick Ratio (TTM) 0.66
Cash Ratio (TTM) 0.11
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 0.72%
Gross margin (TTM) 13.87%
Operating margin (TTM) 1.46%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for CVS.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 8Market Perform 3Outperform 8Overweight 11
1 upgrade, 0 downgrades
Price Target Consensus
Current $90.98
Median $101.50
Consensus $100.75
Low consensus $90.00
High consensus $110.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Barclays maintain Overweight Overweight 2026-05-26
Mizuho maintain Outperform Outperform 2026-05-20
Morgan Stanley maintain Overweight Overweight 2026-05-14
Bernstein maintain Outperform Outperform 2026-05-13
JP Morgan maintain Overweight Overweight 2026-05-12
TD Cowen maintain Buy Buy 2026-05-11
Wells Fargo maintain Overweight Overweight 2026-05-08
UBS maintain Buy Buy 2026-05-07
Barclays maintain Overweight Overweight 2026-05-07
RBC Capital maintain Outperform Outperform 2026-05-07
Truist Securities maintain Buy Buy 2026-05-07
Evercore ISI Group maintain Outperform Outperform 2026-05-07
Baird maintain Outperform Outperform 2026-04-15
Piper Sandler maintain Overweight Overweight 2026-03-31
Bernstein upgrade Market Perform Outperform 2026-03-12
Argus Research maintain Buy Buy 2026-01-28
B of A Securities maintain Buy Buy 2026-01-27
Bernstein maintain Market Perform Market Perform 2026-01-06
JP Morgan maintain Overweight Overweight 2025-12-17
Bernstein maintain Market Perform Market Perform 2025-12-12
Mizuho maintain Outperform Outperform 2025-12-10
UBS maintain Buy Buy 2025-12-10
Morgan Stanley maintain Overweight Overweight 2025-12-10
Piper Sandler maintain Overweight Overweight 2025-12-10
Truist Securities maintain Buy Buy 2025-12-10
Barclays maintain Overweight Overweight 2025-12-10
Baird maintain Outperform Outperform 2025-12-10
Bernstein maintain Market Perform Market Perform 2025-12-05
Wells Fargo maintain Overweight Overweight 2025-11-13
TD Cowen maintain Buy Buy 2025-11-03